Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort

被引:9
作者
Koff, Jean L. [1 ]
Rai, Ashish [2 ]
Flowers, Christopher R. [1 ]
机构
[1] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, 1365 Clifton Rd,Bldg B,Suite 4300, Atlanta, GA 30322 USA
[2] Amer Canc Soc, Atlanta, GA 30329 USA
关键词
DLBCL; Non-Hodgkin lymphoma; Rheumatoid arthritis; Sjogren syndrome; Systemic lupus erythematosus; NON-HODGKIN-LYMPHOMA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; ELDERLY-PATIENTS; RACIAL-DIFFERENCES; RISK; SURVIVAL; CHEMOTHERAPY; RITUXIMAB; SUBTYPES;
D O I
10.1016/j.clml.2017.11.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We used the Surveillance, Epidemiology, and End Results (SEER) eMedicare-linked database to characterize the patterns of presentation, treatment, and survival in older diffuse large B-cell lymphoma (DLBCL) patients with concomitant autoimmune disease. DLBCL patients with autoimmune disease were more likely to be female but otherwise did not differ significantly from other DLBCL patients in demographic data, treatment, or clinical outcomes. Background: Severe immune dysregulation such as seen in autoimmune (AI) disease is known to act as a significant risk factor for diffuse large B-cell lymphoma (DLBCL). However, little is known about the demographics or clinical outcomes of DLBCL that arises in the setting of AI disease. Patients and Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database for patients with a diagnosis from 1999 to 2009 linked to their Medicare claims data through 2011 to characterize the presentation, treatment, and survival patterns in DLBCL patients, including those with rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjgren syndrome, and other B-cellemediated AI diseases. We examined the baseline clinical characteristics for patients with B-celle mediated AI disease, plotted the overall survival and lymphoma-related survival (LRS) for these groups, and compared the median survival times. Results: Patients with DLBCL and AI disease were more commonly female. However, patients with DLBCL and rheumatoid arthritis, SLE, Sjgren syndrome, or other B-cell AI diseases did not differ from other DLBCL patients in any other baseline presenting features and received similar first-line treatment. A trend toward decreased LRS was seen in patients with SLE and DLBCL compared with all other groups, but this difference was not statistically significant in this cohort. Conclusion: In the present retrospective claims-based cohort of older patients with DLBCL, concomitant AI disease was uncommon and was more likely to occur in female DLBCL patients, which likely reflects the greater incidence of AI disease in women. The possibility of lower LRS for SLE patients should be explored in future studies.
引用
收藏
页码:E115 / E121
页数:7
相关论文
共 39 条
[1]  
Adamo M, 2021, SEER program coding and staging manual 2016
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]  
[Anonymous], CA CANC J CLIN
[4]   Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis [J].
Baecklund, E ;
Iliadou, A ;
Askling, J ;
Ekborn, A ;
Backlin, C ;
Granath, F ;
Catrina, AT ;
Rosenquist, R ;
Feltelius, N ;
Sundström, C ;
Klareskog, L .
ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :692-701
[5]   Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis [J].
Baecklund, Eva ;
Backlin, Carin ;
Iliadou, Anastasia ;
Granath, Fredrik ;
Ekbom, Anders ;
Amini, Rose-Marie ;
Feltelius, Nils ;
Enblad, Gunilla ;
Sundstrom, Christer ;
Klareskog, Lars ;
Askling, Johan ;
Rosenquist, Richard .
ARTHRITIS AND RHEUMATISM, 2006, 54 (12) :3774-3781
[6]   Non-Hodgkin's lymphoma in systemic lupus erythematosus [J].
Bernatsky, S ;
Ramsey-Goldman, R ;
Rajan, R ;
Boivin, JF ;
Joseph, L ;
Lachance, S ;
Cournoyer, D ;
Zoma, A ;
Manzi, S ;
Ginzler, E ;
Urowitz, M ;
Gladman, D ;
Fortin, PR ;
Edworthy, S ;
Barr, S ;
Gordon, C ;
Bae, SC ;
Sibley, J ;
Steinsson, K ;
Nived, O ;
Sturfelt, G ;
St Pierre, Y ;
Clarke, A .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1507-1509
[7]   Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].
Bongartz, T ;
Sutton, AJ ;
Sweeting, MJ ;
Buchan, I ;
Matteson, EL ;
Montori, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285
[8]  
Cerhan James R., 2014, Journal of the National Cancer Institute Monographs, P15, DOI 10.1093/jncimonographs/lgu010
[9]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[10]   Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies [J].
Costa, Luciano J. ;
Maddocks, Kami ;
Epperla, Narendranath ;
Reddy, Nishitha M. ;
Karmali, Reem ;
Umyarova, Elvira ;
Bachanova, Veronika ;
Costa, Cristiana ;
Glenn, Martha J. ;
Chavez, Julio C. ;
Calzada, Oscar ;
Lansigan, Frederick ;
Nasheed, Hossain ;
Barta, Stefan K. ;
Zhou, Zheng ;
Jaglal, Michael ;
Chhabra, Saurabh ;
Hernandez-Ilizaliturri, Francisco ;
Xavier, Ana C. ;
Mehta, Amitkumar ;
Peker, Deniz ;
Forero-Torres, Andreas ;
Al-Mansour, Zeina ;
Evens, Andrew M. ;
Cohen, Jonathon B. ;
Flowers, Christopher R. ;
Fenske, Timothy S. ;
Hamadani, Mehdi .
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (02) :161-170